Xing Li1, Shao-Hua Chen2, Jin-Wu Zeng2. 1. Department of Respiratory Medicine, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, China, lixinglijing@126.com. 2. Department of Respiratory Medicine, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, China.
Abstract
BACKGROUND: Lung cancer is the main cause of cancer--related deaths worldwide, and the overall 5-year survival rate of non-small cell lung cancer (NSCLC) remained low. -MicroRNAs had been confirmed to be an important regulator in tumor progression, and they could serve as either tumor promoters or suppressors in NSCLC. OBJECTIVES: To identify the novel cancer-specific biomarkers for NSCLC patients, which may be useful to monitor tumor progression and improve NSCLC patients' survival. METHOD: The expression profile of miR-421 was analyzed in NSCLC samples using public datasets, including The Cancer Genome Atlas and GSE102286. The expression level of miR-421 was detected by reverse transcription-polymerase chain reaction. Cell proliferation and cell cycle were detected by Cell Counting Kit assay, flow cytometry assay, respectively. Kyoto Encyclopedia of Genes and Genomes analysis were applied to determine the biological roles of miR-421, based on the online DAVID system. Statistical comparisons between groups of normalized data were performed using t test or Mann-Whitney U test according to the test condition. RESULTS: In this study, we focused on exploring the roles of miR-421 in NSCLC prognosis and growth. The present study for the first time showed that miR-421 was overexpressed in NSCLC and associated with a shorter overall survival time of patients with NSCLC. Bioinformatics analysis revealed miR-421 was involved in transcription, cell cycle, and insulin signaling pathway regulation. Furthermore, a gain of function assay showed that overexpression of miR-421 could promote NSCLC cell proliferation and cell cycle progression. CONCLUSIONS: Our findings suggest that miR-421 might be a promising prognostic and therapeutic target for NSCLC.
BACKGROUND:Lung cancer is the main cause of cancer--related deaths worldwide, and the overall 5-year survival rate of non-small cell lung cancer (NSCLC) remained low. -MicroRNAs had been confirmed to be an important regulator in tumor progression, and they could serve as either tumor promoters or suppressors in NSCLC. OBJECTIVES: To identify the novel cancer-specific biomarkers for NSCLCpatients, which may be useful to monitor tumor progression and improve NSCLCpatients' survival. METHOD: The expression profile of miR-421 was analyzed in NSCLC samples using public datasets, including The Cancer Genome Atlas and GSE102286. The expression level of miR-421 was detected by reverse transcription-polymerase chain reaction. Cell proliferation and cell cycle were detected by Cell Counting Kit assay, flow cytometry assay, respectively. Kyoto Encyclopedia of Genes and Genomes analysis were applied to determine the biological roles of miR-421, based on the online DAVID system. Statistical comparisons between groups of normalized data were performed using t test or Mann-Whitney U test according to the test condition. RESULTS: In this study, we focused on exploring the roles of miR-421 in NSCLC prognosis and growth. The present study for the first time showed that miR-421 was overexpressed in NSCLC and associated with a shorter overall survival time of patients with NSCLC. Bioinformatics analysis revealed miR-421 was involved in transcription, cell cycle, and insulin signaling pathway regulation. Furthermore, a gain of function assay showed that overexpression of miR-421 could promote NSCLC cell proliferation and cell cycle progression. CONCLUSIONS: Our findings suggest that miR-421 might be a promising prognostic and therapeutic target for NSCLC.
Authors: Jun Hou; Joachim Aerts; Bianca den Hamer; Wilfred van Ijcken; Michael den Bakker; Peter Riegman; Cor van der Leest; Peter van der Spek; John A Foekens; Henk C Hoogsteden; Frank Grosveld; Sjaak Philipsen Journal: PLoS One Date: 2010-04-22 Impact factor: 3.240
Authors: Delong Meng; Shu Yang; Xuechao Wan; Yalong Zhang; Wenhua Huang; Peiqing Zhao; Tao Li; Lianqing Wang; Yan Huang; Tao Li; Yao Li Journal: Int J Biochem Cell Biol Date: 2016-01-28 Impact factor: 5.085
Authors: Wen Cai Zhang; Tan Min Chin; Henry Yang; Min En Nga; Declan Patrick Lunny; Edwin Kok Hao Lim; Li Li Sun; Yin Huei Pang; Yi Ning Leow; Shanneen Rossellini Y Malusay; Priscilla Xin Hui Lim; Jeravan Zili Lee; Benedict Jian Wei Tan; Ng Shyh-Chang; Elaine Hsuen Lim; Wan Teck Lim; Daniel Shao Weng Tan; Eng Huat Tan; Bee Choo Tai; Ross Andrew Soo; Wai Leong Tam; Bing Lim Journal: Nat Commun Date: 2016-06-21 Impact factor: 14.919
Authors: Łukasz Koperski; Marta Kotlarek; Michał Świerniak; Monika Kolanowska; Anna Kubiak; Barbara Górnicka; Krystian Jażdżewski; Anna Wójcicka Journal: Oncotarget Date: 2017-07-25